Scotiabank analyst Nicholas Yulico lowered the firm’s price target on Healthpeak Properties (DOC) to $23 from $24 and keeps an Outperform rating on the shares. The firm is providing updated thoughts on the recent NYC Office sale comparables and commercial mortgage-backed securities, CMBS, issuance, which has led to changes to the ratings of the U.S. Real Estate & REITs in its coverage, the analyst tells investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOC:
- Wedbush upgrades Welltower to Outperform, raises price target to $167
- Healthpeak Properties price target lowered to $24 from $27 at Wedbush
- Healthpeak Properties price target lowered to $24 from $25 at Baird
- Potential Regulatory Changes Threaten Healthpeak Properties’ Investment in Healthcare Real Estate
- Healthpeak Properties: Strong Q4 Performance and Strategic Initiatives Justify Buy Rating